William Blair Has Positive View of FibroGen FY2024 Earnings

FibroGen, Inc. (NASDAQ:FGEN) – Equities researchers at William Blair lifted their FY2024 earnings per share estimates for shares of FibroGen in a note issued to investors on Wednesday, November 13th. William Blair analyst A. Hsieh now anticipates that the biopharmaceutical company will earn ($0.86) per share for the year, up from their prior forecast of ($1.12). William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for FibroGen’s current full-year earnings is ($0.86) per share. William Blair also issued estimates for FibroGen’s Q4 2024 earnings at ($0.20) EPS, Q1 2025 earnings at ($0.10) EPS, Q2 2025 earnings at ($0.10) EPS and FY2025 earnings at ($0.38) EPS.

Separately, StockNews.com assumed coverage on shares of FibroGen in a research report on Thursday, November 14th. They set a “hold” rating for the company.

FibroGen Stock Up 3.7 %

NASDAQ:FGEN opened at $0.35 on Monday. FibroGen has a 52-week low of $0.18 and a 52-week high of $2.93. The stock has a fifty day simple moving average of $0.36 and a 200-day simple moving average of $0.70. The company has a market capitalization of $35.27 million, a PE ratio of -0.27 and a beta of 0.72.

FibroGen (NASDAQ:FGEN) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.21. The firm had revenue of $46.33 million for the quarter, compared to analysts’ expectations of $34.00 million. During the same quarter in the previous year, the firm posted ($0.52) earnings per share.

Institutional Investors Weigh In On FibroGen

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Alpine Global Management LLC purchased a new position in FibroGen during the first quarter worth $25,000. Delap Wealth Advisory LLC acquired a new stake in shares of FibroGen during the first quarter valued at $27,000. Point72 DIFC Ltd boosted its stake in shares of FibroGen by 734.2% during the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 45,990 shares during the last quarter. Doheny Asset Management CA purchased a new stake in FibroGen during the 2nd quarter worth about $48,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in FibroGen in the 1st quarter valued at about $131,000. Hedge funds and other institutional investors own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.